Nune Darbinian1, Armine Darbinyan2, Nana Merabova3, Ahsun Bajwa4, Gabriel Tatevosian5, Diana Martirosyan6, Huaqing Zhao7, Michael E Selzer8, Laura Goetzl9. 1. Center for Neural Repair and Rehabilitation (Shriners Hospitals Pediatric Research Center), Lewis Katz School of Medicine at Temple University, Philadelphia, PA 19140, United States of America. Electronic address: nsarkiss@temple.edu. 2. Department of Pathology, Yale University School of Medicine, New Haven, CT 06520, United States of America. Electronic address: armine.darbinyan@yale.edu. 3. Center for Neural Repair and Rehabilitation (Shriners Hospitals Pediatric Research Center), Lewis Katz School of Medicine at Temple University, Philadelphia, PA 19140, United States of America. Electronic address: mnana@temple.edu. 4. Center for Neural Repair and Rehabilitation (Shriners Hospitals Pediatric Research Center), Lewis Katz School of Medicine at Temple University, Philadelphia, PA 19140, United States of America. Electronic address: tud21230@temple.edu. 5. Center for Neural Repair and Rehabilitation (Shriners Hospitals Pediatric Research Center), Lewis Katz School of Medicine at Temple University, Philadelphia, PA 19140, United States of America. Electronic address: tuf38489@temple.edu. 6. Center for Neural Repair and Rehabilitation (Shriners Hospitals Pediatric Research Center), Lewis Katz School of Medicine at Temple University, Philadelphia, PA 19140, United States of America. Electronic address: tue96857@temple.edu. 7. Department of Clinical Sciences (Biostatistics and Epidemiology), Lewis Katz School of Medicine at Temple University, Philadelphia, PA 19140, United States of America. Electronic address: tuf08292@temple.edu. 8. Center for Neural Repair and Rehabilitation (Shriners Hospitals Pediatric Research Center), Lewis Katz School of Medicine at Temple University, Philadelphia, PA 19140, United States of America. Electronic address: mselzer@temple.edu. 9. Department of Obstetrics & Gynecology, University of Texas, Houston, TX 77030, United States of America. Electronic address: laura.goetzl@uth.tmc.edu.
Abstract
INTRODUCTION: Alterations of white matter integrity and subsequent white matter structural deficits are consistent findings in Fetal Alcohol Syndrome (FAS), but knowledge regarding the molecular mechanisms underlying these abnormalities is incomplete. Experimental rodent models of FAS have shown dysregulation of cytokine expression leading to apoptosis of oligodendrocyte precursor cells (OPCs) and altered oligodendrocyte (OL) differentiation, but whether this is representative of human FAS pathogenesis has not been determined. METHODS: Fetal brain tissue (12.2-21.4 weeks gestation) from subjects undergoing elective termination of pregnancy was collected according to an IRB-approved protocol. Ethanol (EtOH) exposure status was classified based on a detailed face-to-face questionnaire adapted from the National Institute on Alcohol Abuse and Alcoholism Prenatal Alcohol and Sudden Infant Death Syndrome and Stillbirth (PASS) study. Twenty EtOH-exposed fetuses were compared with 20 gestational age matched controls. Cytokine and OPC marker mRNA expression was quantified by Real-Time Polymerase chain reaction (qRT-PCR). Patterns of protein expression of OPC markers and active Capase-3 were studied by Fluorescence Activated Cell Sorting (FACS). RESULTS: EtOH exposure was associated with reduced markers of cell viability, OPC differentiation, and OL maturation, while early OL differentiation markers were unchanged or increased. Expression of mRNAs for proteins specific to more mature forms of OL lineage (platelet-derived growth factor α (PDGFRα) and myelin basic protein (MBP) was lower in the EtOH group than in controls. Expression of the multifunctional growth and differentiation-promoting growth factor IGF-1, which is essential for normal development, also was reduced. Reductions were not observed for markers of early stages of OL differentiation, including Nuclear transcription factor NK-2 homeobox locus 2 (Nkx2.2). Expression of mRNAs for the proinflammatory cytokine, tumor necrosis factor-α (TNFα), and several proinflammatory chemokines was higher in the EtOH group compared to controls, including: Growth regulated protein alpha/chemokine (C-X-C motif) ligand 1 (GRO-α/CXCL1), Interleukin 8/chemokine (C-X-C motif) ligand 8 (IL8/CXCL8), Chemokine (C-X-C motif) ligand 6/Granulocyte chemotactic protein 2 (CXCL16/GCP2), epithelial-derived neutrophil-activating protein 78/chemokine (C-X-C motif) ligand 5 (ENA-78/CXCL5), monocyte chemoattractant protein-1 (MCP-1). EtOH exposure also was associated with an increase in the proportion of cells expressing markers of early stage OPCs, such as A2B5 and NG2. Finally, apoptosis (measured by caspase-3 activation) was increased substantially in the EtOH group compared to controls. CONCLUSION: Prenatal EtOH exposure is associated with excessive OL apoptosis and/or delayed OL maturation in human fetal brain. This is accompanied by markedly dysregulated expression of several chemokines and cytokines, in a pattern predictive of increased OL cytotoxicity and reduced OL differentiation. These findings are consistent with findings in animal models of FAS.
INTRODUCTION: Alterations of white matter integrity and subsequent white matter structural deficits are consistent findings in Fetal Alcohol Syndrome (FAS), but knowledge regarding the molecular mechanisms underlying these abnormalities is incomplete. Experimental rodent models of FAS have shown dysregulation of cytokine expression leading to apoptosis of oligodendrocyte precursor cells (OPCs) and altered oligodendrocyte (OL) differentiation, but whether this is representative of human FAS pathogenesis has not been determined. METHODS: Fetal brain tissue (12.2-21.4 weeks gestation) from subjects undergoing elective termination of pregnancy was collected according to an IRB-approved protocol. Ethanol (EtOH) exposure status was classified based on a detailed face-to-face questionnaire adapted from the National Institute on Alcohol Abuse and Alcoholism Prenatal Alcohol and Sudden Infant Death Syndrome and Stillbirth (PASS) study. Twenty EtOH-exposed fetuses were compared with 20 gestational age matched controls. Cytokine and OPC marker mRNA expression was quantified by Real-Time Polymerase chain reaction (qRT-PCR). Patterns of protein expression of OPC markers and active Capase-3 were studied by Fluorescence Activated Cell Sorting (FACS). RESULTS: EtOH exposure was associated with reduced markers of cell viability, OPC differentiation, and OL maturation, while early OL differentiation markers were unchanged or increased. Expression of mRNAs for proteins specific to more mature forms of OL lineage (platelet-derived growth factor α (PDGFRα) and myelin basic protein (MBP) was lower in the EtOH group than in controls. Expression of the multifunctional growth and differentiation-promoting growth factor IGF-1, which is essential for normal development, also was reduced. Reductions were not observed for markers of early stages of OL differentiation, including Nuclear transcription factor NK-2 homeobox locus 2 (Nkx2.2). Expression of mRNAs for the proinflammatory cytokine, tumor necrosis factor-α (TNFα), and several proinflammatory chemokines was higher in the EtOH group compared to controls, including: Growth regulated protein alpha/chemokine (C-X-C motif) ligand 1 (GRO-α/CXCL1), Interleukin 8/chemokine (C-X-C motif) ligand 8 (IL8/CXCL8), Chemokine (C-X-C motif) ligand 6/Granulocyte chemotactic protein 2 (CXCL16/GCP2), epithelial-derived neutrophil-activating protein 78/chemokine (C-X-C motif) ligand 5 (ENA-78/CXCL5), monocyte chemoattractant protein-1 (MCP-1). EtOH exposure also was associated with an increase in the proportion of cells expressing markers of early stage OPCs, such as A2B5 and NG2. Finally, apoptosis (measured by caspase-3 activation) was increased substantially in the EtOH group compared to controls. CONCLUSION: Prenatal EtOH exposure is associated with excessive OL apoptosis and/or delayed OL maturation in human fetal brain. This is accompanied by markedly dysregulated expression of several chemokines and cytokines, in a pattern predictive of increased OL cytotoxicity and reduced OL differentiation. These findings are consistent with findings in animal models of FAS.
Authors: Philip A May; Barbara Tabachnick; Julie M Hasken; Anna-Susan Marais; Marlene M de Vries; Ronel Barnard; Belinda Joubert; Marise Cloete; Isobel Botha; Wendy O Kalberg; David Buckley; Zachary R Burroughs; Heidre Bezuidenhout; Luther K Robinson; Melanie A Manning; Colleen M Adnams; Soraya Seedat; Charles D H Parry; H Eugene Hoyme Journal: Drug Alcohol Depend Date: 2017-06-15 Impact factor: 4.492
Authors: Fulton T Crews; Rabih Bechara; Lou Ann Brown; David M Guidot; Pranoti Mandrekar; Shilpa Oak; Liya Qin; Gyongyi Szabo; Michael Wheeler; Jian Zou Journal: Alcohol Clin Exp Res Date: 2006-04 Impact factor: 3.455
Authors: Linda Kadi; Ram Selvaraju; Patricia de Lys; Amanda E I Proudfoot; Timothy N C Wells; Ursula Boschert Journal: J Neuroimmunol Date: 2006-03-30 Impact factor: 3.478
Authors: Cynthia J M Kane; Kevin D Phelan; James C Douglas; Gail Wagoner; Jennifer W Johnson; Jihong Xu; Patrick S Phelan; Paul D Drew Journal: Alcohol Clin Exp Res Date: 2013-08-22 Impact factor: 3.455
Authors: Helene L Philogene-Khalid; Mary F Morrison; Nune Darbinian; Michael E Selzer; Joseph Schroeder; Scott M Rawls Journal: Drug Alcohol Depend Date: 2022-01-12 Impact factor: 4.492
Authors: Katrina A Milbocker; Gillian L LeBlanc; Eric K Brengel; Khan S Hekmatyar; Praveen Kulkarni; Craig F Ferris; Anna Y Klintsova Journal: Sci Rep Date: 2022-06-23 Impact factor: 4.996